Potential drug-drug interactions in outpatients with depression of a psychiatry department

被引:6
|
作者
Chen, Yang [1 ]
Ding, Lijun [1 ]
机构
[1] Xiamen Xianyue Hosp, Xiamen 361001, Fujian, Peoples R China
关键词
Drug -drug interactions; Potential drug -drug interactions; Polypharmacy; Depression; Psychotropic drugs; Outpatients; Ding); GENDER-DIFFERENCES; TREATMENT STRATEGY; RISK-FACTORS; PREVALENCE;
D O I
10.1016/j.jsps.2022.12.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This study aims to explore the prevalence and associated risk factors for potential drug-drug interactions (pDDIs) in prescriptions among outpatients with depression, and report the widespread rel-evant drug interactions. Methods: The cross-sectional retrospective study was conducted on outpatients in a psychiatric hospital. We included prescriptions of outpatients with a principal diagnosis of depression from April 1st to June 30th in 2021. The patients were >= 18 years old and treated with two or more drugs including at least one psychotropic drug. pDDIs were detected and identified mainly using Medscape's drug interactions checker. Gender, the number of concomitant drugs, age and diagnosis were analysed as potential risk fac-tors for the occurrence of pDDIs by logistic regression. Results: A total of 13,617 prescriptions were included in the present analysis, and 4222 prescriptions (31.0%) were at risk of 8557 pDDIs. The risk of pDDIs in patients who were prescribed 4-6 drugs (OR: 3.49, 95% CI: 3.11-3.91, p < 0.001) or 7 or more drugs simultaneously (OR: 7.86, 95% CI: 1.58-39.04, p < 0.05) increased compared with patients prescribed 2-3 drugs. Patients with recurrent depressive dis-orders (OR: 1.18, 95% CI: 1.02-1.36, p < 0.05) had an increased risk of pDDIs compared with patients with depressive episodes. In terms of severity of pDDIs identified by Medscape's drug interactions checker, 0.7%, 16.4%, 77.5% and 5.4% of pDDIs were classified as contraindicated, serious, monitor closely and minor, respectively. The most common pDDI was escitalopram + quetiapine (374 prescriptions), which was classified as serious and monitor closely due to different mechanisms of interaction. Increased cen-tral nervous system (CNS)-depressant effect was the most frequent potential clinical adverse outcome of the identified pDDIs. Conclusions: pDDIs in outpatients with depression were prevalent in this retrospective study. The num-ber of concomitant drugs and severity of the disease were important risk factors for pDDIs. The pDDIs of the category monitor closely were the most common, and the CNS-depressant effect was the most fre-quent potential clinical adverse outcome.(c) 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:207 / 213
页数:7
相关论文
共 50 条
  • [31] Investigating Potential Drug-Drug Interactions from Greek e-Prescription Data
    Lalagkas, Panagiotis-Nikolaos
    Poulentzas, Georgios
    Tsiolis, Lampros
    Berberoglou, Eleftherios
    Hadjipavlou-Litina, Dimitra
    Douros, Antonios
    Kontogiorgis, Christos
    Constantinides, Theodoros
    CURRENT DRUG SAFETY, 2022, 17 (02) : 114 - 120
  • [32] Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy
    Ismail, Mohammad
    Khan, Sehrash
    Khan, Fahadullah
    Noor, Sidra
    Sajid, Hira
    Yar, Shazia
    Rasheed, Irum
    BMC CANCER, 2020, 20 (01)
  • [33] Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome
    Pejcic, Ana, V
    Jankovic, Slobodan M.
    Davidovic, Goran
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 58
  • [34] Assessment of potential drug-drug interactions and its associated factors in the hospitalized cardiac patients
    Murtaza, Ghulam
    Khan, Muhammad Yasir Ghani
    Azhar, Saira
    Khan, Shujaat Ali
    Khan, Tahir M.
    SAUDI PHARMACEUTICAL JOURNAL, 2016, 24 (02) : 220 - 225
  • [35] Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis
    Debus, Jane Louisa
    Bachmann, Paula
    Frahm, Niklas
    Mashhadiakbar, Pegah
    Langhorst, Silvan Elias
    Streckenbach, Barbara
    Baldt, Julia
    Heidler, Felicita
    Hecker, Michael
    Zettl, Uwe Klaus
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
  • [36] Ageing with HIV: medication use and risk for potential drug-drug interactions
    Marzolini, Catia
    Back, David
    Weber, Rainer
    Furrer, Hansjakob
    Cavassini, Matthias
    Calmy, Alexandra
    Vernazza, Pietro
    Bernasconi, Enos
    Khoo, Saye
    Battegay, Manuel
    Elzi, Luigia
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (09) : 2107 - 2111
  • [37] POTENTIAL DRUG-DRUG INTERACTIONS IN HOSPITALIZED PATIENTS WITH COVID-19
    Szkutnik-Fiedler, Danuta
    Kwiatkowski, Filip
    Chomej, Monika
    Kolodziej, Dorota
    Michalak, Michal
    Grzeskowiak, Edmund
    Szalek, Edyta
    ACTA POLONIAE PHARMACEUTICA, 2023, 80 (02): : 277 - 287
  • [38] Potential drug-drug interactions in hospitalised haematological patients
    Fernandez de Palencia Espinosa, Ma Angeles
    Diaz Carrasco, Ma Sacramento
    Sanchez Salinas, Andres
    de la Rubia Nieto, Amelia
    Espuny Miro, Alberto
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (06) : 443 - 453
  • [39] Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions
    Vazquez, Marta
    Garcia-Carnelli, Carlos
    Maldonado, Cecilia
    Fagiolino, Pietro
    CANNABINOIDS AND SLEEP: MOLECULAR, FUNCTIONAL AND CLINICAL ASPECTS, 2021, 1297 : 27 - 42
  • [40] The impact of treatment choices on potential drug-drug interactions in hypertensive patients
    Peric, Aneta
    Udilovic, Ana
    Dobric, Silva
    Kovacevic, Sandra Vezmar
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2340 - 2348